S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.
To evaluate the efficacy and safety of S-1 monotherapy, S-1-containing combined chemotherapy and S-1 containing chemoradiotherapy for non-small cell lung cancer (NSCLC), a population-based observational study was performed. The efficacy and safety of the chemotherapies were evaluated at 13 institutes in a prefecture of Japan between April 2011 and March 2015. Datasets were obtained from 282 patients with NSCLC. For either wild-type or mutated epidermal growth factor receptor (EGFR), these three therapy groups generated almost identical response results and toxicity profiles as those in previously reported clinical trials, although the present study appeared to have slightly lower survival rates compared with those in the previous clinical trials. This may be due to the inclusion of patients in poor condition, and S-1 therapy being administered in the second, or later, line of therapy. In conclusion, the present study has confirmed that S-1-containing chemotherapy is effective against wild- and mutated-type EGFR NSCLC, and it is also tolerable in clinical practice.
Tsuchiura Kyodo General Hospital and Regional Cancer Center, Tsuchiura, Ibaraki 300-0053, Japan.
Masaharu
M
Inagaki
Tsuchiura Kyodo General Hospital and Regional Cancer Center, Tsuchiura, Ibaraki 300-0053, Japan.
Yoko
Y
Shinohara
Ibaraki Prefectural Central Hospital and Regional Cancer Center, Kasama, Ibaraki 309-1793, Japan.
Takayuki
T
Kaburagi
Mito Medical Center Hospital, Mito, Ibaraki 311-3193, Japan.
Takeo
T
Endo
Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
Shinsuke
S
Homma
Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
Nobuyuki
N
Hizawa
Tokyo Medical University, Ibaraki Medical Center Hospital, Ami, Ibaraki 300-0395, Japan.
Koji
K
Kishi
Tokyo Medical University, Ibaraki Medical Center Hospital, Ami, Ibaraki 300-0395, Japan.
Hiroyuki
H
Nakamura
Ibaraki Higashi National Hospital, Tokai, Ibaraki 319-1113, Japan.
Kenji
K
Hayashihara
Ibaraki Higashi National Hospital, Tokai, Ibaraki 319-1113, Japan.
Takefumi
T
Saito
Tsukuba Medical Center Hospital and Regional Cancer Center, Tsukuba, Ibaraki 305-8558, Japan.
Koichi
K
Kurishima
Tsukuba Medical Center Hospital and Regional Cancer Center, Tsukuba, Ibaraki 305-8558, Japan.
Hiroichi
H
Ishikawa
Hitachi General Hospital, Hitachi, Ibaraki 317-0077, Japan.
Hideo
H
Ichimura
Hitachi General Hospital, Hitachi, Ibaraki 317-0077, Japan.
Takeshi
T
Nawa
Kasumigaura Medical Center, Tsuchiura, Ibaraki 300-0812, Japan.
Norihiro
N
Kikuchi
Ryugasaki Saiseikai General Hospital, Ryugasaki, Ibaraki 301-0854, Japan.
Kunihiko
K
Miyazaki
Ryugasaki Saiseikai General Hospital, Ryugasaki, Ibaraki 301-0854, Japan.
Takahide
T
Kodama
Division of Respiratory Medicine, Μito Medical Center, Institute of Clinical Medicine, University of Tsukuba, Mito, Ibaraki 310-0015, Japan.
Hiroaki
H
Satoh
Tokyo Medical University, Ibaraki Medical Center Hospital, Ami, Ibaraki 300-0395, Japan.
Kinya
K
Furukawa
S-1; non-small cell lung cancer; observational study; population-based